N-{6-[N-(3-dimethylaminopropyl)-N-methylamino]pyrid-3-yl}-2-chloro-5-(2-morpholinopyrid-4-ylcarbonylamino)benzamide | 295349-54-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-{6-[N-(3-dimethylaminopropyl)-N-methylamino]pyrid-3-yl}-2-chloro-5-(2-morpholinopyrid-4-ylcarbonylamino)benzamide
• 英文别名: N-[4-chloro-3-[[6-[3-(dimethylamino)propyl-methylamino]pyridin-3-yl]carbamoyl]phenyl]-2-morpholin-4-ylpyridine-4-carboxamide
• CAS: 295349-54-1
• 化学式: C₂₈H₃₄ClN₇O₃
• 分子量: 552.076
• InChiKey: IPZSFJIBECFZRR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  39
• 可旋转键数：
  10
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  103
• 氢给体数：
  2
• 氢受体数：
  8

文献信息

• Amide derivatives
  申请人：ASTRAZENECA AB

  公开号：US20030186966A1

  公开（公告）日：2003-10-02

  This invention concerns amide derivatives of Formula (I) wherein X is CH or N; Y is CH or N; m is 0-3; R 1 is a group such as hydroxy, halogeno, trifluoromethyl, cyano, mercapto, nitro, amino, carboxy and carbamoyl; n is 0-3; R 2 is a group such as hydroxy, halogeno, trifluoromethyl, cyano, mercapto, nitro, amino, carboxy and (1-6C)alkoxycarbonyl; R 3 is hydrogen, halogeno, (1-6C)alkyl or (1-6C)alkoxy; q is 0-4; and Q is a group such as aryl, aryloxy, aryl-(1-6C)alkoxy, arylamino, N-(1-6C)alkyl-arylamino and aryl-(1-6C)alkylamino; or pharmaceutically-acceptable salts or in-vivo-cleavable esters thereof; processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of diseases or medical conditions mediated by cytokines.

  本发明涉及式（I）的酰胺衍生物，其中X为CH或N; Y为CH或N; m为0-3; R1为羟基、卤素、三氟甲基、氰基、巯基、硝基、氨基、羧基和氨基甲酰基等基团; n为0-3; R2为羟基、卤素、三氟甲基、氰基、巯基、硝基、氨基、羧基和(1-6C)烷氧基甲酰基等基团; R3为氢、卤素、(1-6C)烷基或(1-6C)烷氧基; q为0-4; Q为芳基、芳氧基、芳基-(1-6C)烷氧基、芳基氨基、N-(1-6C)烷基芳基氨基和芳基-(1-6C)烷基氨基等基团; 或其药学上可接受的盐或体内可降解的酯; 以及制备它们的方法、含有它们的制药组合物以及它们在通过细胞因子介导的疾病或医疗状况的治疗中的应用。
• AMIDE DERIVATIVES
  申请人：AstraZeneca AB

  公开号：EP1163212A1

  公开（公告）日：2001-12-19
• PYRIDINE CARBOXAMIDE DERIVATIVES FOR USE AS ANTICANCER AGENTS
  申请人：AstraZeneca AB

  公开号：EP1831198B1

  公开（公告）日：2009-04-08
• [EN] AMIDE DERIVATIVES<br/>[FR] DERIVES AMIDES
  申请人：ASTRAZENECA AB

  公开号：WO2000055120A1

  公开（公告）日：2000-09-21

  This invention concerns amide derivatives of Formula (I) wherein X is CH or N; Y is CH or N; m is 0-3; R1 is a group such as hydroxy, halogeno, trifluoromethyl, cyano, mercapto, nitro, amino, carboxy and carbamoyl; n is 0-3; R2 is a group such as hydroxy, halogeno, trifluoromethyl, cyano, mercapto, nitro, amino, carboxy and (1-6C)alkoxycarbonyl; R3 is hydrogen, halogeno, (1-6C)alkyl or (1-6C)alkoxy; q is 0-4; and Q is a group such as aryl, aryloxy, aryl-(1-6C)alkoxy, arylamino, N-(1-6C)alkyl-arylamino and aryl-(1-6C)alkylamino; or pharmaceutically-acceptable salts or in-vivo-cleavable esters thereof; processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of diseases or medical conditions mediated by cytokines.
• [EN] CHEMICAL COMPOUNDS<br/>[FR] COMPOSES CHIMIQUES
  申请人：ASTRAZENECA AB

  公开号：WO2006067445A2

  公开（公告）日：2006-06-29

  [EN] The invention relates to chemical compounds, or pharmaceutically acceptable salts thereof of the formula (I): which possess CSF-1R kinase inhibitory activity and are accordingly useful for their anti cancer activity and thus in methods of treatment of the human or animal body. The invention also relates to processes for the manufacture of said chemical compounds, to pharmaceutical compositions containing them and to their use in the manufacture of medicaments of use in the production of an anti-cancer effect in a warm blooded animal such as man.
  [FR] L'invention concerne des composés chimiques, ou des sels pharmaceutiquement acceptables de ceux-ci, représentés par la formule (I). Lesdits composés possèdent une activité inhibitrice de kinases CSF-1R et sont par conséquent utiles pour leur activité anticancéreuse et donc dans des méthodes de traitement du corps d'un être humain ou d'un animal. L'invention concerne également des procédés de fabrication desdits composés chimiques, des compositions pharmaceutiques les contenant ainsi que leur utilisation dans la fabrication de médicaments destinés à être utilisés dans la production d'un effet anticancéreux chez un animal à sang chaud tel que l'homme.